Brief Definitive Report

Cooperative Roles of CTLA-4 and Regulatory T Cells in Tolerance to an Islet Cell Antigen


Department of Pathology, University of California, San Francisco, CA 94143

Abstract

Adoptive transfer of ovalbumin (OVA)-specific T cells from the DO.11 TCR transgenic mouse on a Rag−/− background into mice expressing OVA in pancreatic islet cells induces acute insulitis and diabetes only if endogenous lymphocytes, including regulatory T cells, are removed. When wild-type OVA-specific/Rag−/− T cells, which are all CD25−, are transferred into islet antigen–expressing mice, peripheral immunization with OVA in adjuvant is needed to induce diabetes. In contrast, naive CTLA-4−/−/Rag−/− OVA-specific T cells (also CD25−) develop into Th1 effectors and induce disease upon recognition of the self-antigen alone. These results suggest that CTLA-4 functions to increase the activation threshold of autoreactive T cells, because in its absence self-antigen is sufficient to trigger autoimmunity without peripheral immunization. Further, CTLA-4 and regulatory T cells act cooperatively to maintain tolerance, indicating that the function of CTLA-4 is independent of regulatory cells, and deficiency of both is required to induce pathologic immune responses against the islet self-antigen.

Key words: autoimmunity • tolerance • diabetes • T cell activation • interferon gamma

Introduction

Multiple mechanisms are known to induce tolerance in mature T cell populations in peripheral lymphoid tissues. These mechanisms include anergy, deletion, and suppression by regulatory T (Treg) cells (1–4). We and others have shown previously that the inhibitory T cell receptor, CTLA-4, plays an essential role in maintaining unresponsiveness to tolerogenic forms of foreign and self-antigens (5–7). However, it is still not clearly established if CTLA-4 limits the magnitude of initial T cell activation or inhibits continued T cell expansion and differentiation into effector cells. Many investigators have also demonstrated a critical role of Treg cells in maintaining tolerance to a variety of self-antigens, including islet antigens (8, 9), but again the mechanisms by which Treg cells inhibit responses of autoreactive lymphocytes are not well established.

Most autoimmune diseases show complex, multigenic patterns of susceptibility. The existence of multiple susceptibility genes suggests that several pathways of self-tolerance need to be disrupted in order to trigger pathologic autoreactivity. In this study, we have examined the consequence of deleting CTLA-4 and eliminating Treg cells on the development of diabetes in a transgenic mouse model. Our results show that in the absence of an exogenous immunogenic stimulus acute, severe diabetes develops only if both CTLA-4 and Treg cells are nonfunctional. The cooperative role of these two tolerogenic pathways suggests that they serve distinct functions, perhaps at different stages of the T cell response.

Materials and Methods

Mice. DO11.10 TCR transgenic mice were purchased from Jackson Laboratory, and Rag2−/− mice were purchased from Taconic Laboratories. Rat insulin promoter (RIP)-mOVA/Balb/c mice (referred to as RIP-mOVA mice), expressing OVA under the control of the RIP, were provided by Dr. William Heath (The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia). The CTLA-4−/−/DO11.10 mouse has been described previously (10). RIP-mOVA mice, CTLA-4−/−/DO.11 mice, and the DO11.10 TCR transgenic mice were bred onto a Rag2−/− background. DO.11 homozygous mice were bred with the RIP-mOVA mice to generate DO.11 × RIP-mOVA mice.

Abbreviations used in this paper: RIP, rat insulin promoter; Treg cell, regulatory T cell.
in B, the blood glucose levels in the immunized RIP-mOVA/Rag

a priming signal. Naive CTLA-4

phocyte-deficient recipient, whereas naive wild-type DO.11 T cells require

with 200 µl complete medium (RPMI 1640 supplemented with 1 mM glutamine, penicillin, streptomycin, nonessential amino acids, sodium pyruvate, HEPES [all from Life technologies], 10% FCS [Sigma-Aldrich], and 5 x 10^{-5} M B-mercapto-ethanol) and stimulated with 1 µg/ml OVA peptide (residues 323–339) for a total of 6 h. Brefeldin A (10 µg/ml) (Epicenter) was added for the last 3 h of incubation. The cells were then surface stained with CD4-PerCP and the clonotypic antibody KJ1-26, since the TCR is internalized upon activation.

Adoptive Transfers and Immunization. For T cell transfers, LNs (axillary, brachial, mesenteric, popliteal, and submandibular) and spleens were pooled, red cells lysed, and single cell suspensions made. The cells were stained with CD4-PerCP and KJ1-26-APC to determine the number of DO.11 cells. Indicated numbers of cells were injected i.v. through the tail vein. Where indicated, mice were immunized s.c. in the flank, 24 h after adoptive transfer with 200 µg OVA peptide emulsified in IFA (Difco). For transfers of CD25hi and CD25lo DO.11 cells, pooled LN and spleen cells were stained with CD4-PerCP, CD25-PE, and CD62L-FITC. Cells were purified using high speed sorting (MoFlo; Cytomation) to separate CD25hiCD62Llo DO.11 (Treg cells) and CD25loCD62Lhi DO.11 (responder) populations.

Monitoring for Diabetes. Adoptively transferred mice were followed for the development of diabetes by biweekly monitoring of blood glucose levels using an Elite glucometer (Bayer Corp.).

Histology. Mice were killed using CO2 narcosis, and the pancreas was removed aseptically. For hematoxylin and eosin staining, the tissues were fixed in 10% phosphate-buffered formalin. For immunohistochemistry, acetone-fixed frozen tissues were sectioned, incubated in a 0.05% diaminobenzidine and 0.003% H2O2 solution, rinsed, counterstained with hematoxylin, and observed under light microscopy.

Results and Discussion

CTLA-4-/- DO.11 T Cells Induce Diabetes without Immunization. We have previously shown that OVA-specific DO.11/Rag-/- cells induce acute diabetes only in Rag-/- RIP-mOVA recipients (not in Rag-/- littermates) and that peripheral (s.c.) immunization with OVA in adjuvant is required (unpublished data). In striking contrast, seen after transfer of wild-type DO.11 cells and immunization were not different from those after transfer of CTLA-4-/- DO.11 cells and no immunization (P = 0.376). (C) Wild-type and CTLA-4-/- DO.11 T cells are phenotypically naive; plots shown were gated on KJ1-26+ cells.
Figure 2. CTLA-4−/− DO.11 T cells cause severe insulitis in RIP-mOVA/Rag−/− mice. Naive wild-type or CTLA-4−/− DO.11 T cells (10 million per mouse) were transferred into RIP-mOVA/Rag−/− recipients and immunized with OVA peptide and IFA where indicated. The mice were killed 13 d after transfer, and the pancreas were either formalin fixed and stained with hematoxylin and eosin (left) or frozen, acetone fixed, and stained with KJ1-26 (right) and observed under 40X magnification. Wild-type DO.11 T cells (A and B); wild-type DO.11 T cells and immunized with OVA peptide + IFA (C and D); CTLA4−/− DO.11 T cells (E and F). Representative sections for each experimental group are shown.

Figure 3. Transferred wild-type and CTLA-4−/− DO.11 T cells show similar activation profiles on encountering antigen. Naive CTLA-4−/− DO.11 or wild-type DO.11 cells (10 million per mouse) were transferred into RIP-mOVA/Rag−/− recipients, and some mice were immunized s.c. with 200 μg OVA peptide in IFA as indicated. Peripheral (PLN) and pancreatic (PANC) LNs were harvested 3 d later and cells were stained for CD4 and KJ1-26 and CD62L (A) and CD25 (B) expression. Plots shown are gated on KJ1-26+ cells. Numbers refer to the percentage of positive cells in the quadrant.
we show here that transfer of T cells from CTLA-4−/− DO.11/Rag−/− donors induced diabetes in RIP-mOVA/Rag−/− recipients in the absence of peripheral immunization (Fig. 1, A compared with B). Importantly, the CTLA-4−/− T cells were not diabetogenic in lymphocyte-sufficient RIP-mOVA recipients, suggesting that even CTLA-4−/− T cells can be controlled by Treg cells (reference 11 and Fig. 1 A).

A possible explanation for the increased pathogenicity of the CTLA-4−/− T cells is that these cells are activated by endogenous antigens before adoptive transfer. However, as shown previously (5) both wild-type and CTLA-4−/− DO.11 T cells on a Rag−/− background express high levels of CD62L and undetectable levels of CD25 and are thus phenotypically and functionally naive (Fig. 1 C). It is also conceivable that CTLA-4 is involved in the function of Treg cells, we examined the accumulation of wild-type or CTLA-4−/− DO.11 cells adoptively transferred into RIP-

Figure 4. T cell activation in the absence of CTLA-4 and endogenous lymphocytes. Naive wild-type or CTLA-4−/− DO.11 T cells (10 million per mouse) were transferred into either RIP-mOVA or RIP-mOVA/Rag−/− recipients. Mice were killed on day 13, and pancreatic and peripheral LN cells were stained for the presence of KJ1-26 CD4+ cells or re-stimulated with 1 μg/ml OVA peptide for 6 h, and stained for intracellular IFNγ. Shown are DO.11 cells as the percentage of total mononuclear cells recovered from peripheral and pancreatic LNs of RIP-mOVA/Rag−/− mice (A) or RIP-mOVA recipients (C). IFNγ-producing DO.11 cells as the percentage of total KJ1-26 CD4+ cells in either pancreatic or peripheral LNs of RIP-mOVA/Rag−/− (B) or RIP-mOVA (D) recipients. The data present pooled results of two independent experiments using a total of six mice per experimental group. In A, no difference was observed in numbers of wild-type and CTLA-4−/− DO.11 cells recovered from the peripheral (P = 0.09) or pancreatic LN (P = 0.08). In B, CTLA-4−/− cells recovered from the pancreatic LN produced significantly more IFNγ that wild-type cells (P = 0.007).
mOVA hosts. As is evident in Fig. 4 C, the presence of endogenous lymphocytes prevented expansion of both wild-type DO.11 and CTLA-4−/− DO.11 T cells, both in the periphery and at the site of antigenic stimulation, the pancreatic LN. In addition, the cells did not differentiate into effectors, indicated by the lack of IFNγ production (Fig. 4 D). Thus, both Treg cells and CTLA-4 control inappropriate T cell expansion and effector differentiation in response to a self-antigen, and it does not appear that they regulate different components of the T cell response, e.g., expansion and effector cell development.

**Treg Cells Prevent Disease Induced by CTLA-4−/− DO.11 T Cells.** Balb/c animals are relatively resistant to autoimmune disease, possibly due to high activity of Treg cells (12). As demonstrated earlier (Figs. 1, A and B), we have never been able to break tolerance and induce diabetes in Balb/c animals that have intact lymphoid compartments. To confirm that acute diabetes required a deficiency of Treg cells, we asked if purified Treg cells could protect Rag-deficient animals from diabetes. To reconstitute Treg cells, we isolated OVA-specific CD25+/H11002 T cells from DO.11 × RIP-mOVA mice, as described previously (13), and cotransferred these with CTLA-4−/− DO.11 T cells into RIP-mOVA Rag−/− recipients. As shown in Fig. 5 A, the CD25+ DO.11 T cells completely prevented disease induction by the CTLA-4−/− T cells, whereas cotransfer of CD25− DO.11 cells was not protective. These results are consistent with the view that RIP-mOVA/Rag−/− mice develop disease because they lack CD25+ Treg cells. Although it has been shown that cells transferred to lymphopenic animals are prone to induce autoimmune disease chiefly due to their homeostatic proliferation in this environment (14), we doubt that homeostatic proliferation alone is sufficient to induce disease in our model, since only cotransfer of CD25+ but not CD25− T cells had an inhibitory effect on the progression of diabetes. Furthermore, the recovery of DO.11 cells was not significantly different in the pancreatic and peripheral LNs of mice regardless of whether they received CD25− or CD25+ DO.11 cells (Fig. 5 B).

The experiments in this work show that wild-type, antigen-specific T cells attack antigen-expressing islets and cause acute disease only if the T cells are first activated by intentional peripheral immunization with the same antigen in adjuvant. However, CTLA-4−/− T cells are pathogenic even without such immunization, implying that in the absence of CTLA-4, a self-antigen behaves like an immunogen. The pathogenicity of both immunized wild-type T cells and naive CTLA-4−/− T cells is prevented by the presence of endogenous Treg cells. Since both CTLA-4 and Treg cells must be absent in order to result in severe disease, these results suggest that the two mechanisms of tolerance do not serve the same role. Thus, although it has been suggested that CTLA-4 is involved in the suppressive function of Treg cells (11, 15), our results indicate that this cannot be the only function of CTLA-4.

A likely model for the cooperativity of CTLA-4 and Treg cells is that these inhibitory influences may act at different stages in the life of a T cell. A major function of CTLA-4 may be to increase the threshold for initial T cell activation (16), such that self-antigens by themselves are incapable of activating naive T cells. Thus, CTLA-4 would prevent normal DO.11 cells from being pathogenic unless its inhibitory effect was overcome by immunization with adjuvant. This role is consistent with the finding that wild-type T cells are not pathogenic unless they are first exposed to peripheral immunization with antigen and adjuvant, but CTLA-4−/− T cells are pathogenic after encounter with self-antigen alone. Treg cells may function later in T cell responses to block proliferation and differentiation at the site of self-antigen, regardless of the initiating trigger. This is why both activated wild-type T cells and naive CTLA-4−/− T cells are prevented from causing disease if Treg cells are present. It will be important to develop systems for addressing the possible sequential function of different tolerance mechanisms and to determine if genetic polymorphisms of CTLA-4 (17) need to be complemented by deficiencies of Treg cells in order to induce spontaneous autoimmune diseases in humans and experimental models.

We thank S. Jiang for help with cell sorting.

This work was supported by National Institutes of Health grant RO1 AI33297 to A.K. Abbas and grant K08 AI054366-01 to M.P. Eggena, V. Nagabhushanam is supported by the Juvenile Diabetes Research Foundation, and L.S.K Walker is supported by the Wellcome Trust.
References